Cipla has announced its financial results for the first quarter of fiscal year 2026, reporting a consolidated net profit of ₹1,298 crore, a 10.3% increase compared to ₹1,178 crore in the same quarter last year. The company's total revenue from operations also saw an increase of 3.9%, reaching ₹6,957 crore compared to ₹6,694 crore in the corresponding period of the previous fiscal year.
The company's operating profit, or earnings before interest, taxes, depreciation, and amortization (EBITDA), grew by 3.6% to ₹1,778 crore, compared to ₹1,716 crore year-on-year. The firm's margin remained stable at 25.6% year-on-year. Following the earnings report, Cipla's shares were trading at ₹1,532 apiece, up 2.96% on the NSE.
Cipla's "One India Business" demonstrated a 6% year-on-year growth for the quarter, surpassing ₹3,000 crore for the first time in the opening quarter of any financial year. Key therapies within India, including respiratory, urology, cardiac, anti-diabetes, and anti-infectives, grew faster than the market, with the overall chronic mix at 61.5% as per IQVIA MAT June 2025. Cipla successfully launched Voltido Trio, a significant addition to its respiratory portfolio, during the quarter.
The company's North America business delivered quarterly revenue of $226 million, supported by traction in differentiated assets. Cipla launched Nano Paclitaxel vials (ANDA) and Nilotinib Capsules (NDA) during the quarter. However, North America sales declined 7% year-on-year to ₹1,933 crore for the June quarter.
Cipla's revenue growth in the "One Africa" business continued with an overall increase of 11% year-on-year in USD terms. The prescription business is ranked No. 2 in the market. Emerging Markets and Europe posted a healthy revenue growth of 8% year-on-year in USD terms. Africa sales grew 14% year-on-year to ₹871 crore for the June quarter as compared with ₹766 crore in the April-June period of last year.
Cipla's Managing Director and Global CEO, Umang Vohra, noted the company's One-India business grew at 6% year-on-year during the quarter. He stated that key therapies in the branded prescription business continued to outpace market growth, the trade generics business growth trajectory is back on track, and anchor brands of the consumer health business maintained their leadership position. Vohra added that the company will focus on growing key markets, further building flagship brands, investing in the future pipeline, and focusing on resolutions on the regulatory front.
Analysts tracked by Bloomberg estimated Cipla's Q1 profit at Rs 1,198 crore, but the company topped the estimates with a profit of Rs 1298 crore. Revenue was up 3.9% to Rs 6,957 crore, versus a Bloomberg estimate of Rs 7,057 crore. Ebitda was up 3.6% to Rs 1,778 crore, compared to an estimated Rs 1,728 crore.
Cipla's consolidated net profit for the quarter ending June 2025 was ₹1291.61 crore, up 10% compared to ₹1175.46 crore in the year-ago quarter. On a quarter-on-quarter basis, profit was 6.2% higher than ₹1,221.84 crore in Q4 FY25.
